Alpha Tau Medical nine-month 2026 net loss more than triples to $98.9 million
DRTS•Alpha Tau Medical reported a net loss of $98.9 million for the nine months ended September 30, 2026, more than triple the year-earlier loss. Cash and deposits totaled $99.8 million, while the company reported a 100% response rate among six evaluable patients in its REGAIN trial.
1. Financial results and trials
Alpha Tau Medical’s net loss more than tripled to $98.9 million for the nine months ended September 30, 2026, compared with a year earlier. Net financial expenses rose to $58.5 million, primarily due to remeasurement of warrant liabilities. Cash, cash equivalents, short-term deposits and restricted deposits increased 30% from December 31, 2025, to $99.8 million at September 30, 2026. The REGAIN recurrent glioblastoma trial recorded a 100% objective response rate among six evaluable patients, including five complete responses; top-line results from the pivotal ReSTART recurrent skin cancer trial are expected in Q1 2027, followed by a potential FDA submission.




